Dr. Jonathan Javitt, Founder, Chairman and CEO of NRx Pharmaceuticals, was interviewed for a broadcast hosted by AdvisorShares.
AdvisorShares is an institutional investor and holder of NRXP stock.
NRX-100 is an IV ketamine formulation being submitted to regulators as an alternative treatment for acute suicidal crises in certain types of depression.
Kadima Neuropsychiatry Institute, featured in the documentary (begins around the 24 minute mark of the documentary), has been identified as a planned HOPE Flagship Clinic acquisition.
Dr. Jonathan Javitt, Founder, Chairman and CEO of NRx Pharmaceuticals, was interviewed for a broadcast hosted by AdvisorShares.
AdvisorShares is an institutional investor and holder of NRXP stock.
The Big Biz Show interviews Jonathan C. Javitt, M.D., M.P.H. Founder, Chairman and CEO of NRx Pharmaceuticals and Co-CEO of HOPE Therapeutics discussing applications of Ketamine and it’s treatment for acute suicidality, anti-depressant/chronic pain oral medication NRX-101, how dopamine acts as a neurotransmitter in the brain and the recent investor workshop at the Mar-A-Lago Club.
The Big Biz Show interviews Jonathan C. Javitt, M.D., M.P.H. Founder, Chairman and CEO of NRx Pharmaceuticals and Co-CEO of HOPE Therapeutics, discussing the opportunity for HOPE Therapeutics in developing its nationwide network of interventional psychiatry clinics to help address the national epidemic of suicidality and mental health, the planned financing and upcoming presentations by management in San Francisco and at Mar-A-Lago.
Jonathan Javitt, MD, MPH, Founder, Chairman, and Chief Scientist of NRx Pharmaceuticals, presents at NobleCon20 – Noble Capital Markets’ Twentieth Annual Emerging Growth Equity Conference at Florida Atlantic University on Tuesday December 3, 2024
The Big Biz Show interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals, discussing IV Ketamine and it’s treatment for acute suicidality, anti-depressant oral medication NRX-101 and the launch of Hope Therapeutics.
What Are NRX-101 and NRX-100? It’s against this backdrop that NRx Pharmaceuticals sought to develop two new pharmacological treatments for bipolar depression with a risk of suicide.
